Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University.
PRESTO, Japan Science and Technology Agency.
Biol Pharm Bull. 2020;43(4):608-615. doi: 10.1248/bpb.b19-00740.
Liver transplantation and hepatocyte transplantation are effective treatments for severe liver injuries, but the donor shortage is a serious problem. Therefore, hepatocyte-like cells generated from human induced pluripotent stem (iPS) cells with unlimited proliferative ability are expected to be a promising new transplantation resource. The technology for hepatic differentiation from human iPS cells has made great progress in this decade. The efficiency of hepatic differentiation now exceeds 90%, making it possible to produce nearly homogeneous hepatocyte-like cells from human iPS cells. Because there is little contamination of undifferentiated cells, there is a lower risk of teratoma formation. To date, the transplantation of human iPS cell-derived hepatocyte-like cells has been shown to have therapeutic effects using various liver injury model mice. Currently, studies are underway using model animals larger than mice. The day when human iPS cell-derived hepatocyte-like cells can be used as cellular medicine is surely approaching. In this review, we introduce the forefront of regenerative medicine applications using human iPS cell-derived hepatocyte-like cells.
肝移植和肝细胞移植是治疗严重肝损伤的有效方法，但供体短缺是一个严重的问题。因此，具有无限增殖能力的人诱导多能干细胞（iPS）产生的肝样细胞有望成为一种有前途的新移植资源。人 iPS 细胞向肝分化的技术在过去十年中取得了重大进展。肝分化的效率现在超过了 90%，使得几乎可以从人 iPS 细胞中产生同质的肝样细胞。由于未分化细胞的污染很少，畸胎瘤形成的风险较低。迄今为止，使用各种肝损伤模型小鼠已经证明了人 iPS 细胞衍生的肝样细胞的治疗效果。目前，正在使用大于小鼠的模型动物进行研究。人 iPS 细胞衍生的肝样细胞作为细胞药物使用的那一天肯定即将到来。在这篇综述中，我们介绍了使用人 iPS 细胞衍生的肝样细胞进行再生医学应用的最前沿技术。
